US Tariff Threat Rattles Pharma Sector
The pharmaceutical sector faced significant selling pressure following a Financial Times report. The U.S. administration is reportedly considering tariffs of up to 100% on certain imported medicines. This potential move targets companies that have not committed to manufacturing within the United States, presenting drugmakers with a choice between higher costs or relocating operations.
How Tariffs Could Be Implemented
Sources suggest these proposed duties might be enacted under a specific trade law, offering the administration a potential legal avenue. This follows previous tariff actions that faced legal challenges. The uncertainty over how these tariffs would be enforced, and if any companies would receive exemptions, creates significant concern for drugmakers exporting heavily to the U.S.
Market Sell-Off Hits Major Stocks
Heavyweights Feel the Pinch
Major Indian pharmaceutical stocks saw immediate drops. Sun Pharmaceutical Industries Ltd. fell 4% during trading. Cipla Ltd. was down 2.14%, and Apollo Hospitals Enterprise Ltd. declined 2.02%. Other notable losers included Wockhardt Ltd. (down 2.17%), Narayana Hrudayalaya Ltd. (down 2.16%), and Laurus Labs Ltd. (down 2.16%).
Widespread Selling Pressure
The impact extended beyond the largest companies. Entero Healthcare Solutions Ltd. dropped 2.14%, Concord Biotech Ltd. slipped 2.13%, and Dishman Carbogen Amcis Ltd. declined 1.99%. Ajanta Pharma Ltd. was down 1.91%, Gufic BioSciences Ltd. and FDC Ltd. fell 1.89% each, while Shilpa Medicare Ltd. retreated 1.88%. The widespread selling pressure was evident in the Nifty Pharma index, which closed down 3%.
Sector Outlook Amid Uncertainty
The prospect of new U.S. tariffs introduces considerable risk for pharmaceutical companies already contending with pricing pressures and complex regulations. Investor apprehension is expected to continue until details emerge on specific exemptions and enforcement, likely affecting stock values across the sector.